Sanjay Gupta, MD; Sadiq Al-Samarrai, MD; Prakash S. Masand, MD; Barbara J. Lentz, RN; Peggy J. Keller, RNC, MS; and Thomas M. Droney, RN
Forgot your login? GET HELP
Background: Recent reports have shown that
risperidone, which has established antipsychotic efficacy, is
effective and safe in a once-daily dosing regimen.
Method: The efficacy and safety of once-daily
risperidone were assessed in a retrospective study of 27 patients
with a variety of psychiatric disorders who were attending a
community day treatment program. Their DSM-IV diagnoses included
schizophrenia, schizoaffective disorder, bipolar disorder, major
depression with psychosis, and posttraumatic stress disorder.
They had received once-daily risperidone for a mean of more than
18 months.
Results: Disorders of most patients were
controlled with once-daily dosages of 1 to 6 mg/day of
risperidone. The nighttime once-daily risperidone dosage was well
tolerated by patients. In addition, there was no increase in
antipsychotic-related side effects, and compliance was enhanced.
Conclusion: Risperidone was well tolerated, and
no patient needed antiparkinsonian medications even at high
dosages of risperidone once daily.
Prim Care Companion J Clin Psychiatry 2000;2(2):55-57
https://doi.org/10.4088/PCC.v02n0205
© Copyright 2000 Physicians Postgraduate Press, Inc.